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The medicinal mushroom Agaricus blazei Murill from the Brazilian rain forest has been used in traditional medicine and as health
food for the prevention of a range of diseases, including infection, allergy, and cancer. Other scientists and we have examined
whether there is scientiﬁc evidence behind such postulations. Agaricus blazei M is rich in the immunomodulating polysaccharides,
β-glucans, and has been shown to have antitumor, anti-infection, and antiallergic/-asthmatic properties in mouse models, in
addition to anti-inﬂammatory eﬀects in inﬂammatory bowel disease patients. These eﬀects are mediated through the mushroom’s
stimulation of innate immune cells, such as monocytes, NK cells, and dendritic cells, and the amelioration of a skewed Th1/Th2
balance and inﬂammation.
1.Introduction
The edible Basidiomycetes mushroom Agaricus blazei Murill
(AbM), a.k.a. Agaricus subrufescens Peck (already described
in 1893), and Agaricus brasiliensis Wasser [1]( Figure 1), of
Brazilian rain forest origin is used in traditional medicine
against cancer and various diseases [2, 3]. It is related to the
champignon (Agaricus bisporus) and is shown to be rich in
immunomodulating substances such as highly branched β-
1,3-/1,6-glucans [4]a n dp r o t e o g l y c a n s[ 5]. These are known
ligands for CD11b/18 (complement receptor 3, CR3) [6],
dectin-1 [7], and toll-like receptor 2 (TLR2) [8]o nm o n o -
cytes, dendritic cells (DC), granulocytes, and NK cells [9]o f
the innate immune system. AbM is also shown to contain
agaritine and ergosterol (provitamin D2) that is found to
induceapoptosisinleukemiccells[10]andinhibittumor-in-
duced angiogenesis [11], respectively, as well as isoﬂavonoids
with potent hypoglycemic action that could be useful against
diabetes mellitus [12] .A b Mi sr e p o r t e dt oh a v ea n t i t u m o r
propertiesinmousemodelsofﬁbrosarcoma,myeloma,ovar-
ian, lung, and prostate cancer, and in human studies against
gynecological cancer (increased NK cell activity and quality
of life) and leukemia [13].
2. Effects on Infection andAllergy
We found that an AbM-based extract (AndoSan, http://www
.immunopharma.net/), also containing the medicinal Basid-
iomycetesmushroomsHericiumerinaceum(15%)andGrifola
frondosa (3%), given orally increased survival from bacterial
sepsis in mice inoculated i.p. a day afterward with pneumo-
cocci (Figure 2)[ 14]o rf e c a lb a c t e r i a[ 15]. The mixed mush-
room extract also protected against IgE-mediated allergy
in a mouse model when given p.o. either before or after
ovalbumin s.c. sensitization of the animals (Figure 3)[ 16].
In supernatants of cultured spleen cells from the sacriﬁced
AbM-treated mice, there was an increased T-helper cell 12 Advances in Pharmacological Sciences
Figure 1: Agaricus blazei Murill. Photo NutriCon. The mushroom
is cultivated commercially for the health food market in Japan,
China, and Brazil. The AbM-based AndoSan extract is produced in
Japan and developed and distributed by ImmunoPharma AS, Oslo,
Norway.
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Figure 2: 5-6-week-old female inbred NIH/Ola mice were given
either200μLofAndoSanAbMextractorphosphate-buﬀeredsaline
(PBS) intragastrically a day before i.p. injection of 1 million colony-
forming units of Streptococcus pneumoniae serotype 6B. There was
a signiﬁcant diﬀerence (P<0.05) between survival after treatment
with AndoSan (red line) and PBS (black line). From [14], permis-
siongrantedforrepublicationbyScandJImmunol,wheretheﬁgure
was originally published.
response relative to the allergy-inducing Th2 response. The
observation ﬁts with the reduced speciﬁc serum IgE levels
in these animals and shows that also adaptive immunity
is engaged by the mushroom. Since the original Th1/Th2
dichotomy [17] says that the antitumor and anti-infection
Th1 response is inversely related to the Th2 response, the
spleen cell ﬁnding above also helps explain the concomitant
antiallergic, antitumor, and antiinfection eﬀects of AbM.
Moreover, this agrees with the very interesting report ﬁnding
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Figure 3: Female NIH/Ola mice were given either 200μlo ft h e
AndoSan AbM-based extract or PBS intragastrically on day 1 and
10μg of ovalbumin s.c. on day 0 and again on day 20, before exsan-
guination for serum on day 26. IgE antiovalbumin levels were lower
in the AbM- than in the PBS-treated groups (P = 0.002). Similar
results were found if AbM extract or PBS was given 3 weeks after
theallergenimmunization(notshown,pleasesee[16]).IgG2aanti-
ovalbumin levels (Th1 response) tended to show the opposite result
(not shown). From [16], previously published by a BMC journal,
which allows reuse.
that AbM extract ameliorated a skewed Th1/Th2 balance
both in asthma-induced and in tumor-bearing mice [18]. It
is previously known that patients with advanced cancer have
malfunctional Th1 cells and a Th2-skewed immune system
[19]. However, it is not known whether AbM contributed to
rectify a possibly induced Th1/Th2 imbalance in the above-
mentioned sepsis models in mice [14, 15].
We have previously compared the biological potency of 5
diﬀerent AbM products orally in a blinded experiment in the
pneumococcal sepsis model and found that only AndoSan,
given orally 24h prior to bacterial challenge, induced statis-
tically signiﬁcant lower bacteremia and higher survival rate
than did saline given prechallenge in control mice [13]. The
outcome of this experiment, actually done in 2003 but not
published until 2008, was the basis for choosing AndoSan
(then called AbM extract A) in our further studies. Syner-
gies between components from the three mushrooms in the
said extract may explain its enhanced eﬃcacy against sepsis.
Tuberculosis is another serious infection although it actually
only develops into active disease in 10% of those infected
withM. tuberculosis bacilli. Hence, in contrast to the exposed
but healthy individuals, the tuberculosis patients represent
a selected group, which is not prone to the tubercle bacilli’s
strong ability to elicit Th1-type cellular immune responses,
for example, the normal reaction to the BCG vaccine. In fact,
the Th1/Th2 imbalance in these patients is shown by their
higher frequency of allergy when compared with healthy
controls [20, 21]. Although a β-glucan from yeast had a pro-
tective eﬀect against M. bovis, BCG infection in a mouse
model [22], the eﬀect of AbM has not to our knowledge been
examined in tuberculosis.Advances in Pharmacological Sciences 3
3. Anti-InﬂammatoryEffect
In a human phase I study in 15 healthy volunteers, we
recently found no side eﬀects after intake of the AbM-based
AndoSan extract [23, 24]. In particular, there were no signif-
icant changes in general blood parameters and no negative
eﬀectsonkidney,liver,orpancreasfunction.Thisagreeswith
a toxicity study over two years in rats [25], which rather
found that animals ingesting the highest AbM concentration
lived the longest, presumably due to reduced cancer de-
velopment. In the mentioned phase I study, AbM extract
had an anti-inﬂammatory eﬀect as shown by significantly
reduced levels of proinﬂammatory cytokines. Although
this is contrary to our in vitro ﬁndings of increased
production of proinﬂammatory cytokines by monocytes,
monocyte-derived DC (MDDC), and human umbilical vein
endothelial cells (HUVEC), we did, as a consequence of
the phase I trial, conduct a clinical pilot study at our
hospital on patients with the inﬂammatory bowel diseases,
ulcerative colitis and Crohn’s disease. The result was a signif-
icant decrease in plasma levels of proinﬂammatory cytokines
after 12 days of AndoSan intake orally and also decreased
levels of the inﬂammatory marker calprotectin in feces of
ulcerative colitis patients [24]. Figure 4 shows that MIP-
1β, IL-6, IL-8, MCP-1, IL-1β, G-CSF, and GM-CSF levels
were reduced in the blood of ulcerative colitis patients
and MIP-1β,M C P - 1 ,I L - 8 ,I L - 1 β, G-CSF, IL-17, GM-CSF,
and IL-2 levels in blood of Crohn’s patients, respectively.
This anti-inﬂammatory property of AbM may also be of
importance for the mushroom’s therapeutic eﬀect on allergy
and asthma in mouse models [18, 21], both of which are
inﬂammatory conditions, and it may bear promise for use
against autoimmune diseases. In addition, it may explain
some of AbM’s antitumor eﬀects discussed below.
4.Mechanism:Stimulationof Immune Cells
The reason for the forceful and swift engagement of innate
immunity when encountering an edible and harmless mush-
room, such as AbM, is its sharing of pathogen-associated
molecular patterns (PAMP) with other highly poisonous
species. Such mushrooms and fungi are usually a health
threat due to the action of their toxins, for example, mus-
cimol from Amanita muscaria and the vasoconstrictor er-
gotamine from Claviceps purpurea,o ri n v a s i o ni ni m m u -
nodeﬁcient patients (e.g., Aspergillus fumigatus)o rn o r m a l
individuals (e.g., Stachybotrys chartarum).
PAMP, such as β-glucans, which form the main cell wall
skeleton in mushrooms and fungi and are their signature
molecule, are recognized immediately by so-called pattern-
recognition receptors (PRR) [26], such as TLR2, dectin-1,
and CR3. One can exploit this immune reaction by using an
innocent mushroom such as Agaricus blazei Mt oe n h a n c e
thebody’sprotectionagainstseriousdiseases.AlthoughAbM
induced NF-κB activation via stimulation of TLR2 on cells
in vitro [27], the AbM-based mushroom extract AndoSan
had anti-inﬂammatory eﬀect in inﬂammatory bowel disease
patientsinvivo[24].Inadditiontomonocytes,granulocytes,
and DC, also NK cells bear such PRR [9] and are stimulated
by AbM in vitro, for example, to induce increase in cytokine
production, expression of the adhesion molecule CD11b on
monocytes and granulocytes, and ROS and NO− production
in the latter cells [28]. An AbM extract also gave a dose-
dependent increase in release of proinﬂammatory cytokines
from HUVEC in culture [29]. Since human skin endothelial
cells can express all 10 TLR genes [30], TLR-binding of AbM
was probably one mechanism behind the above ﬁnding in
HUVEC. This demonstrates that AbM also aﬀects EC, which
are important parttakers in the innate immune response. In
a human study, AbM has been shown to increase NK cell
activity in cancer patients [31]. Another important group
of receptors on macrophages and other innate immune cells
are cytosolic NOD (nucleotide-binding and oligomerization
domain-) like receptors (NLR). These receptors detect con-
served bacterial molecular signatures within the host cells,
similar to recognition of β-glucans via surface receptors or
so-called “danger signals,” alerting the immune system of
hazardous environments [32], and “cross-talk” with TLR on
DC [33].
It is also known that AbM can activate the alternative
pathway of complement [34], giving binding of the CR3
ligand, iC3b, to particulate AbM and thus contribute to
the AbM engagement of the phagocytic CR3. Moreover,
the formation of complement activation split products and
chemotaxins—C3a and C5a—when also the terminal com-
plementpathwayisactivatedwillleadtotheirbindingtoC3a
and C5a (CD88) receptors, respectively, and chemotaxis of
the immune cells towards a C3a and C5a gradient and hence
towards the AbM source.
Animal studies have shown that although β-glucans can
enter the proximal small intestine, the speciﬁc β-1,3-glucan
backbone is indigestible [35]. In vivo, AbM most proba-
bly engage Peyer’s patches in the intestines both via their
abundant β-glucans and other immunomodulating sub-
stances such as proteoglycans, which may be transported to
macrophagesand DC afterbeing taken up fromthe gastroin-
testinal lumen by M cells. Another possibility is direct uptake
oforstimulationbysuchsubstancesofDCviatheirprocesses
into the gastrointestinal lumen or by intestinal macrophages
that may fragment the glucans for transport to the bone
marrow and reticuloendothelial system for further release
and stimulation of other immune cells [35]. Previously, AbM
has in fact been shown to stimulate endothelial cells in vitro
[29]. Sorimachi et al. [36] demonstrated that ethanol (50%)
precipitation of water extracts of the AbM fruiting body
or its supernatant, rather than of the mycelium, induced
TNFα,I L - 8 ,a n dN O − secretion in bone-marrow-derived
rat macrophages. Since the complex β-1,3-/1,6-glucansfrom
AbMinduceddiﬀerentcellularactivitiesthanthemainlyglu-
cose-containing β-1,4-glucan from its nonmedicinal cousin
A. bisporus (the champignon) [37], both diﬀerences in
content, structure, and branching of their β-glucans must be
highly important for the mushrooms’ biological properties.
Especially, β-1,3-glucans seem to be essential for immuno-
logical activity [37]. Interestingly, also a low-molecular-
weight polysaccharide isolated from AbM has been reported
to suppress tumor growth and angiogenesis in vivo [38].
Pyroglutamate is found to be another such small substance4 Advances in Pharmacological Sciences
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Figure 4: Bar graphs (mean and standard error the mean (SEM)) with levels of cytokines (pg/mL) MIP-1β, IL-6, IL-8, and MCP-1 (a)
and IL-1β, G-CSF, and GM-CSF (b) in stimulated (LPS 1ng/mL) whole blood ex vivo from eleven patients (unless otherwise stated) with
ulcerative colitis prior to (day 0) and after AndoSan consumption for 12 days. Days 0 and 12 after stimulation are depicted by the ﬁrst
and second bars from the left, respectively. For MIP-1β and IL-8, measurements in nine out of ten patients were available. Corresponding
measurements from eleven patients with Crohn’s disease (unless otherwise stated) were signiﬁcantly reduced for cytokines MIP-1β,M C P - 1 ,
IL-8,andIL-1β (c)andG-CSF,IL-17,GM-CSF,andIL-2(d).ForMIP-1βandIL-8,measurementsintenoutofelevenpatientswereavailable.
Despite remeasurement of MIP-1β after dilution of plasma 1/10, high out of range values still occurred. Accordingly, the true concentrations
of MIP-1β were even higher. The P values between the bar graphs compare with the cytokine levels at day 0 prior to the intake of AndoSan.
From [24] where the data was part of scatter plots in Scand J Immunol.
[39]. Since also the anti-allergic eﬀect of AbM extract seems
to be owing to low-molecular-weight substances (Hetland G,
unpublished results) in a mouse model, other smaller and
simpler substances than β-glucans in AbM could very well
be as important for the mushroom’s biological eﬀects.
Most probably the mushroom extract also aﬀects the
intestinal ﬂora,whichcomprises10times morebacteriathan
cells in our entire body. Bacteria in the gut are known to
produceessentialvitaminsandsoforth,forexample,bacteria
that can ferment soy beans and produce K2 vitamin that is
important for calcium metabolism [49]. It is probable that
also intestinal bacteria either produce metabolites during
digestion of AbM extract or produce analytes after them-
selves being stimulated by AbM. Such molecules may beAdvances in Pharmacological Sciences 5
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Figure 5: Role of the mushroom Agaricus blazei Murill in immune system modulation and disease control. It is assumed that besides β-
glucans also other, yet unknown substances in the mushroom, probably of low molecular weight, do parttake in the action. IL-12 is the
cytokine from the monocyte/dendritic cell that stimulates Th0.
biologically active after uptake from the gut and may aﬀect
the host.
The PAMP or NOD signature-bearing pathogens are
annihilated immediately by the patrolling innate immune
cells. Some of these like monocytes and DC—directors of the
immunesystemorchestratingthelinkageofinnateandadap-
tiveimmunity—processantigensfromthemushrooms/fungi
and present them together with self HLA II molecules for
CD4 T helper cells, thus engaging adaptive immunity against
the intruders.
Recently, we examined AbM-stimulated MDCC and
found a signiﬁcantly increased production of various cytok-
ines [50]. This agrees with microarray studies in vitro of
promonocytic THP-1 cells incubated with the AbM extract,
whichshowedupregulationformostofgenesassociatedwith
immune function, including the gene for IL-23α subunit—
a Th1 cytokine in the IL-12 family [10]. In fact, the AbM
extract induced even higher production of cytokines TNFα,
IL-1β and MCP-1, and G-CSF than did cells stimulated
with an appropriate concentration of 0.5μg/mL of LPS [50].
Hence, MDDC may in some respect be even more primed
to defense against mushrooms/fungi than against Gram-
negativebacteria.AtourDepartmentofCellularTherapy,we
construct autologous DC vaccines for clinical trials against
various human cancers, by electroporating isolated cancer
mRNA into dendritic cells harvested from the same patients.
Benko et al. [33] have proposed the emerging of ligands of
the innate recognition systems as new adjuvant candidates
for vaccine design. In line with this school of thought, we are
currently examining whether the above AbM extract may be
used as immune adjuvant in such anti-cancer DC vaccines,
similar to studies on DNA vaccines in the mouse against
hepatitis B virus and mouth-and-foot diseases [51, 52]. In
these vaccines, AbM was found to increase levels of antigen-
speciﬁc antibodies as well as to promote proliferation of T
cells, illustrating engagement of adaptive immunity. Figure 5
shows a cartoon of the proposed role of AbM in immune
system modulation and the resulting disease control.
InFigure 6,thebalancebetweenthediﬀerentThrespons-
es is depicted as the Ying and Yang of adaptive immunity.
The committed cells are characterized by expression of the
speciﬁctranscriptionfactors;T-betforTh1,GATA-3forTh2,
FoxP3 for Tregs, and RORγtf o rT h 1 7c e l l s[ 53]. The cartoon
shows that whereas both Th1 and Th2, cells inhibit Th17 and6 Advances in Pharmacological Sciences
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Treg cells, Th1 inhibits Th2, and Th17 inhibits Treg cells.
It is noteworthy that in Crohn’s disease, which is proposed
to be a Th1/Th17-type autoimmune disease, we found sig-
nificant reduction in plasma levels of IL-2 (Th1 cytokine)
and IL-17 after intake of the AbM-based AndoSan extract by
the patients [24]. In the other patients with ulcerative coli-
tis, which is proposed to have a Th2-type autoimmune path-
ogenesis, we found that the IL-4 and IL-13 levels tend-
ed to decrease, although not statistically significantly, after
AndoSan’s intake [24].
5. Antitumor Effects andProposed
Mechanismbehind
As mentioned, the Agaricus mushroom is reported to inhibit
various tumors [10], including hematological cancers such
as myeloma in a recent mouse model [43] and leukemia
in a human study [42]. One proposed mechanism behind
the antitumor eﬀects of AbM is the induction of apoptosis
in tumor cells, which is demonstrated in vitro [40]. This is
conﬁrmed by the microarray ﬁnding of increased expression
of genes inducing apoptosis as well as inhibition of cell
division [46] in PBMC from patients with hepatitis C virus
infection who drank AbM extract for 1 week. Other contrib-
uting mechanisms are (i) the known antitumor action of
ergosterol [11, 54] contained in AbM extract, (ii) the anti-
inﬂammatory eﬀect of AbM [23, 24], which may reduce
levels of the “tumor-friendly” neoangiogenic and granulo-
cyte-chemoattractant factor IL-8 and thus may also decrease
intratumor formation of reactive nitrogen and oxygen spe-
ciesthatmayhampertheinﬁltrationofcytotoxicTcells[55],
and (iv) the amelioration of the proposed skewed Th1/Th2
balance in advanced cancer [18]. There is a well-established
connection between inﬂammation and tumorigenesis [56],
and it is known that organs with chronic inﬂammation are
prone to cancer, for example, the colon in inﬂammatory
bowel diseases, the pancreas after chronic pancreatitis, and
the liver secondary to chronic viral hepatitis. Since up to
1/4 of all cancers are estimated to be caused by underlying
infections and inﬂammation [57], there has lately been a
novel interest for the use of anti-inﬂammatory treatment
in cancer therapy [45]. Hence, both the anti-inﬂammatoryAdvances in Pharmacological Sciences 7
Table 1: Reported in vivo antitumor eﬀect of the mushroom Agaricus blazei Murill.
Tumor/related activity In vivo eﬀects of Agaricus bM Refs. (no., year, country)
Fibrosarcoma Inhibition of tumor size and neoangiogenesis [4] 1994, [40] 1998, [3] 2001,
[39] 2004, Japan
Gynecological cancer∗ Increased NK-cell activity and increased quality of
life (QOL) [31] 2004, Republic of Korea
Ovarian cancer Inhibition of metastasis [41], 2005 Japan
Lung cancer Inhibition of metastasis [39] 2004, [41] 2005, Japan
Leukemia∗ Inhibition [42] 1994, Japan
Myeloma Inhibition of tumor size [43] 2007, Japan
Prostate cancer Reduced tumor growth and neoangiogenesis
No signiﬁcant eﬀect on PSA values∗
[44] 2009, Taiwan
[45] 2010, Japan
Carcinogenicity No [25] 2008, Republic of Korea
∗Human studies, otherwise studies in mice.
Table 2: Clinical studies with Agaricus blazei Murill (AbM).
Patients disease No. of
subjects Treatment Clinical eﬀect Refs. (no., year, country)
Acute nonlymphocytic
leukemia 10 Chemo + AbM Inhibition of leukemic cells [42], 1994, Japan
Gynecological cancer 100 Chemo + AbM Kyowa or placebo,
9wk
↑ NK cell activity, ↑ QOL [31], 2004, Republic of
Korea
IFNα-resistant chron.
HCV infection 4 AndoSan extract 60mL/d for 7d
Insigniﬁcant ↓ HCV load, but ↑
IFNαβ receptor and “antitumor gene”
expression
[46], 2006, Norway
Chron. HBV infection 4 AbM extract 1.5g/d, 12mo Normalized liver function; ↓ASAT ↓
ALAT levels [47], 2007, Taiwan
Diabetes type 2 72 AbM 1.5g/d or placebo 12wk Improved insulin resistance [48], 2008, Taiwan
Healthy volunteers 15 AndoSan 60mL/d for 12d No toxicity, Anti-inﬂammatory [23], 2009, Norway
Inﬂammatory bowel
diseases (∗Ulcerative
colitis and Mb Crohn)
21 AndoSan 60mL/d for 12d
Anti-inﬂammatory; ↓
proinﬂammatory cytokines in blood
and ↓∗calprotectin in feces
[24], 2011, Norway
Abbreviations: ASAT aspartate aminotransferase, ALAT alanine aminotransferase, QOL quality of life. AndoSan is an AbM-based extract also containing 15%
H. erinaceum and 3% G. frondosa.
[23, 24] and anti-infection [14, 15]p r o p e r t i e so fA b M
that we have disclosed may contribute to the mushroom’s
antitumor activity. Interestingly, whereas there was a little,
nonsigniﬁcant reduction in HCV load in serum in the
mentionedclinicalpilottrialin4patientswithchronicIFNα-
resistant HCV infection, the gene for IFNαβ receptor was
signiﬁcantly upregulated by the 7 days AbM treatment [46].
Currently at our hematological department, we are con-
ducting a placebo-controlled, double-blinded phase II trial
in patients with multiple myeloma, who have been drinking
the AbM-based AndoSan extract as a supplementary treat-
ment. These patients are subjected to standard high-dose
chemotherapyandautologoushematopoieticstemcelltrans-
plantation after the harvesting of the cells at our Department
of Cellular Therapy. Patients with multiple myeloma were
chosen for such a clinical trial because there is no curative
therapy for this cancer today-only life-extending treatment.
IntheotherknownclinicalstudieswithAbM,themushroom
was reported to have positive eﬀect against nonlymphocytic
leukemia [42] and to increase quality of life and NK-cell
activity in blood of gynaecological cancer patients on high-
dose chemotherapy [31]. In a small AbM study on prostate
cancer in patients enrolled after radical prostatectomy, there
was no reduction in their prostate-speciﬁc antigen (PSA)
levels [58]. However, there were no placebo controls, and the
study included many with PSA values below the guideline
of 0.2ng/mL of PSA. That study is in contrast with the
ﬁndings of AbM-induced apoptosis for prostate cancer cells
and inhibited tumor growth and antiangiogenic eﬀect in a
mouse model [44]. Interestingly, a recent paper reported
evidence for suppressed growth and invasiveness of human
breast cancer cells in vitro after treatment with a blend of
AbM and other medicinal mushrooms [59]. Table 1 gives an
overview over the reported in vivo antitumor eﬀects of the
Agaricus bM mushroom, and Table 2 shows clinical studies
with this mushroom.8 Advances in Pharmacological Sciences
6. Conclusions
The medicinal mushroom Agaricus bM has been shown
to have beneﬁcial eﬀects on a range of diseases including
cancer, infections, allergy/asthma, and inﬂammatory disor-
ders. The explanation is the mushroom’s engagement of
innateimmunity,whichis“broad-spectered.”Whenadaptive
immunity then is engaged through the stimulation of DC,
it results in an enhanced Th1 antitumor and anti-infection
response relative to the proallergic Th2 response. Thus,
AbMamelioratestheTh2-skewedbalancefoundinadvanced
cancer, mycobacterial infections and allergy and asthma. In
addition, there may be a general anti-inﬂammatory eﬀect of
AbM, which may be therapeutical for inﬂammatory bowel
diseases and augment the mushroom’s antitumor and antial-
lergy/antiasthma properties. Hence, AbM extract may show
promiseasaprophylacticumandasanadditivetreatmentfor
quite diﬀerent and some serious diseases.
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